{
  "trial_id": "NCT03665545",
  "overall_assessment": "likely_ineligible",
  "inclusion": [],
  "exclusion": [
    {
      "criterion": "Any other vaccination given within 2 weeks before first IMA950 vaccination.",
      "label": "triggers",
      "evidence": "unknown"
    },
    {
      "criterion": "Diagnosis of immunodeficiency or active autoimmune disease requiring systemic treatment within the past 3 months or a documented history of clinically severe autoimmune disease, or a condition other than glioblastoma that requires systemic steroids (> 10mg/day prednisone or equivalent) or immunosuppressive agents.",
      "label": "triggers",
      "evidence": "unknown"
    },
    {
      "criterion": "Patients with evidence of history bleeding diathesis.",
      "label": "triggers",
      "evidence": "unknown"
    },
    {
      "criterion": "Pregnant or breastfeeding patients, or expecting to conceive or father children within the projected duration of the trial, starting with the pre-screening or screening visit through 120 days after the last dose of trial treatment.",
      "label": "triggers",
      "evidence": "unknown"
    },
    {
      "criterion": "Has a known additional malignancy that is progressing or requires active treatment.",
      "label": "triggers",
      "evidence": "unknown"
    },
    {
      "criterion": "Is currently participating and receiving study therapy or has participated in a study of an investigational agent and received study therapy or used an investigational device within 4 weeks of the first dose of treatment.",
      "label": "triggers",
      "evidence": "unknown"
    },
    {
      "criterion": "Has a known history of active TB (Bacillus Tuberculosis)",
      "label": "triggers",
      "evidence": "unknown"
    },
    {
      "criterion": "Hypersensitivity to pembrolizumab or any of its excipients.",
      "label": "triggers",
      "evidence": "unknown"
    },
    {
      "criterion": "Has had a prior anti-cancer monoclonal antibody within 4 weeks prior to study Day 1 or who has not recovered (i.e., \u2264 Grade 1 or at baseline) from adverse events due to agents administered more than 4 weeks earlier.",
      "label": "triggers",
      "evidence": "unknown"
    },
    {
      "criterion": "Has had prior chemotherapy, targeted small molecule therapy, or radiation therapy within 2 weeks prior to study Day 1 or who has not recovered (i.e., \u2264 Grade 1 or at baseline) from adverse events due to a previously administered agent.",
      "label": "triggers",
      "evidence": "unknown"
    },
    {
      "criterion": "Has known history of, or any evidence of active (non-infectious) pneumonitis that required(s) steroids.",
      "label": "triggers",
      "evidence": "unknown"
    },
    {
      "criterion": "Has an active infection requiring systemic therapy.",
      "label": "triggers",
      "evidence": "unknown"
    }
  ],
  "notes": "Patient has a history of anaplastic astrocytoma and is currently undergoing treatment, which may make them ineligible for the trial.",
  "_meta": {
    "topic_id": "1",
    "trial_id": "NCT03665545",
    "model": "llama3.1:8b",
    "run_tag": "llama31_8b_full_top100",
    "top_k": 100
  }
}